InVisionFirst®-Lung is an NGS-based liquid biopsy test that detects actionable genes relevant to the treatment and management of advanced non-small cell lung cancer (NSCLC)
Challenges we face with testing tumor tissue in advanced NSCLC
- Approximately 80% of NSCLC patients do not have adequate tumor specimen for complete tissue genotyping for all eight guideline-recommended biomarkers.1
- ~1 in 2 patients with advanced or metastatic NSCLC may be eligible for a targeted therapy.2
- Turn-around time for tissue specimen collection-to-analysis is usually longer than for liquid biopsy testing and may not be the optimal approach for all patients.1
InVisionFirst®-Lung is F.A.S.T. approach to biomarker testing
Focused approach tailored for advanced NSCLC patients
Actionable results to inform patient management
Sensitive & Specific to accurately identify tumor mutations found at very low levels in blood
Timely results delivered within 5 days*
“My liquid biopsy test has potentially bought me several more years that I wouldn’t have had otherwise. That’s something that money can’t buy.”
When results from EGFR single nucleotide variants (SNVs) and insertion and deletions (indels); rearrangements in ALK, NTRK1, RET and ROS1; and SNVs for BRAF are not available
When tissue-based CGP is infeasible (i.e. quantity not sufficient (QNS) for tissue-based CGP or invasive biopsy is medically contraindicated).
For patients progressing on or after chemotherapy or immunotherapy who have not been tested for EGFR SNVs and indels; rearrangements in ALK, NTRK1, RET and ROS1; and SNVs for BRAFs, and for whom tissue-based CGP is infeasible;
For patients progressing on EGFR tyrosine kinase inhibitors (TKIs).
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients